ARTICLE

Volume 10,Issue 4

Cite this article
7
Citations
37
Views
26 December 2025

Performance Evaluation of Autologous Thrombin Produced from Platelet‑rich Plasma (PRP) Tubes

Qiang Liu* Meng Wang1
Show Less
1 Zhuhai Longtime Biological Technology Co., Ltd., Zhuhai 519000, Guangdong, China
JMDS 2025 , 10(4), 185–192; https://doi.org/10.18063/JMDS.v10i4.1206
© 2025 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Thrombin derived from bovine sources is commonly used to arrest bleeding during surgical procedures. However, there are risks associated with the use of bovine-derived thrombin, such as postoperative bleeding and the risk of infection in patients. Therefore, it is essential to develop a technology to generate autologous thrombin. In this study, autologous thrombin was produced from platelet-poor plasma (PPP) obtained using PRP tubes, mixed with 10% calcium gluconate, and halloysite nanotubes (HNTs), and evaluated the stability of prepared thrombin when stored at room temperature. The experiment demonstrated that the combination of 3 ml of platelet-poor plasma (PPP), 2.3 ml of 10% calcium gluconate, and a minimum of 1.5 mg of HNTs produces autologous thrombin with enhanced activity and stability, providing experimental evidence for its potential clinical application.

Keywords
autologous thrombin
stability
10% calcium gluconate
platelet-poor plasma
halloysite nanotubes
References

[1] Al Dieri R, De Laat B, Hemker HC, 2012, Thrombin Generation: What Have We Learned? Blood Reviews, 26(5): 197-203.

[2] Jasani B, Donaldson LJ, Baxter-Smith DC, et al., 1977, Topical Thrombin and Control of Wound Haematoma. Lancet, 310(8033): 332-333.

[3] Ofodile FA, Sadana MK, 1991, The Role of Topical Thrombin in Skin Grafting. Journal of the National Medical Association, 83(5): 416-418.

[4] Codispoti M, Mankad PS, 2002, Significant Merits of a Fibrin Sealant in the Presence of Coagulopathy Following Paediatric Cardiac Surgery: Randomised Controlled Trial. European Journal of Cardio-Thoracic Surgery, 22(2): 200-205.

[5] Kajitani M, Ozdemir A, Aguinaga M, et al., 2000, Severe Hemorrhagic Complication Due to Acquired Factor V Inhibitor After Single Exposure to Bovine Thrombin Product. Journal of Cardiac Surgery, 15(6): 378-382.

[6] Beghi E, Gandolfo C, Ferrarese C, et al., 2004, Bovine Spongiform Encephalopathy and Creutzfeldt-Jakob Disease: Facts and Uncertainties Underlying the Causal Link Between Animal and Human Diseases. Neurological Sciences, 25(3): 122-129.

[7] Kumar V, Madsen T, Zhu H, et al., 2006, Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device. The Journal of Extra-Corporeal Technology, 37(4): 390-395.

[8] Rawtani D, 2012, Multifarious Applications of Halloysite Nanotubes: A Review. Reviews on Advanced Materials Science, 30(3): 282-295.

[9] Satish S, Tharmavaram M, Rawtani D, 2019, Halloysite Nanotubes as a Nature's Boon for Biomedical Applications. Nanobiomedicine, 6(11): 1849.

[10] Trapaidze A, 2015, Integration of Thrombin-Binding Aptamers in Point-of-Care Devices for Continuous Monitoring of Thrombin in Plasma.

[11] Feng Y, Luo X, Wu F, et al., 2022, Systematic Studies on Blood Coagulation Mechanisms of Halloysite Nanotubes-Coated PET Dressing as Superior Topical Hemostatic Agent. Chemical Engineering Journal, 428: 132049.

[12] Clauss A, 1957, Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica, 17(4): 237-246.

Share
Back to top